NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Kura Oncology, Inc. (KURA) Stock Analysis

Kura Oncology, Inc. (KURA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

KURA

$13.25

+$0.10 (+0.76%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KURA with… →

KURA Key Statistics

As of Sep 4, 2026
Trading
Open
$12.94
Previous Close
$13.15
Day's Range
12.89–13.27
52-Week Range
7.36–13.90
Volume
1.31M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.43
Valuation
Market Cap
$1.18B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
15.26
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.40
Financials (FY)
Revenue (FY)
$67.48M+25.24%
Net Income (FY)
−$278.67M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
88.96M
1-Year Return
+62.98%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
1.79M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

KURA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+27.53%
2025+19.29%
2024−39.43%
2023+15.87%
2022−11.36%
2021−57.13%
2020+137.53%
2019−2.07%
2018−8.24%
2017+159.32%
2016 (partial year)+46.04%

As of September 4, 2026.

KURA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$67.48M−$278.67M−412.9%
2024$53.88M−$173.98M−322.9%
2023$0.00−$152.63M—
2022$0.00−$135.84M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$67.48M$67.43M−$303.63M−$278.67M−412.9%
2024$53.88M$53.88M−$193.20M−$173.98M−322.9%
2023$0.00$0.00−$165.80M−$152.63M—
2022$0.00—−$139.87M−$135.84M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

KURA Valuation vs Biotechnology Median

Median of 656 stocks
MetricKURABiotechnology medianvs median
P/S ratio15.2615.260% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Kura Oncology, Inc. (KURA) is capitalised at $1.18B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 260.

KURA last closed at $13.25 on September 4, 2026. That is +$0.10 (+0.76%) against the previous close. The 52-week range on file runs from $7.36 to $13.90. The latest close sits 80.08% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $67.48M. Against the prior fiscal year total of $53.88M, that is a change of +25.24%. The same year closed with a net loss of $278.67M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −3.4.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $67.48M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 15.26. On price-to-sales that is 0% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +62.98%. Across 10 years the annualized return works out at +8.41%. The reported beta is 0.43. Daily returns over the trailing 10 years annualize to a volatility of 68.55%.

Growth & Income

No dividend is on file for KURA.

So far in 2026 the price is +27.53%. Across the complete calendar years on file, 2017 returned +159.32% and 2021 returned −57.13%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Kura Oncology, Inc. (KURA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Kura Oncology, Inc. KURA $1.18B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Kura Oncology, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Kura Oncology, Inc.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Visit website →